The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Jorveza

0.5 milligram(s) Orodispersible tablet

Dr. Falk Pharma GmbHEU/1/17/1254/007-011

Main Information

Trade NameJorveza
Active SubstancesBudesonide
Strength0.5 milligram(s)
Dosage FormOrodispersible tablet
Licence HolderDr. Falk Pharma GmbH
Licence NumberEU/1/17/1254/007-011

Group Information

ATC CodeA07EA06 budesonide

Status

Authorised/WithdrawnAuthorised
Licence Issued20/05/2020
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of LicenceMedicinal product subject to restricted medical prescription (see Annex I: Summary of Product Characteristics, section 4.2).
Marketing StatusUnknown

Documents

Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website
« Back